Talphera, Inc. - $tlph STOCK NEWS

Talphera, Inc. completes rebranding to Talphera and announces first patient enrollment in NEPHRO CRRT study. Cash and investments at $9.4 million as of December 31, 2023, with expected PMA submission by end of 2024. Conference call scheduled for March 6, 2024.

Talphera, Inc. (Nasdaq: TLPH) announces a reduction in the size of its Board of Directors from ten to seven members. Three directors have resigned voluntarily, aiming to enhance corporate governance practices and align the Board's composition with the company's current strategy. The focus remains on obtaining FDA approval for Niyad™ and creating value for shareholders.

Talphera, Inc. (TLPH) to Release Q4 and Full-Year 2023 Financial Results, Host Webcast and Conference Call

Talphera, Inc. announced a total of $26 million of committed capital including $8 million from a partial monetization of DSUVIA royalties and milestones, $6 million of equity issued at a first closing, $10 million of committed capital upon the announcement of positive NEPHRO registration trial data, and an additional $2 million if Talphera stock trades above a specified price following the NEPHRO registration trial announcement. The total committed funding is expected to provide sufficient capital to fund Talphera through a potential FDA approval of Niyad targeted for the first half of 2025. The equity offering transaction with Nantahala Capital and Rosalind Advisors totals $18 million, with $6 million at the first closing, $10 million at the second closing upon Talphera announcing the achievement of the NEPHRO registration trial's primary endpoint and a statistically significant secondary endpoint, and an additional $2 million if Talphera stock trades at a specified price for 5 days after the announcement of the NEPHRO registration trial data. Abhinav Jain of Nantahala Capital Management will join Talphera's Board of Directors at closing, expected on January 19, 2024.